Systemic Sclerosis Sine Scleroderma as a Rare Etiology of Chronic Intestinal Pseudo-Obstruction

Main Article Content

Mitchell Edwards
Jennifer Ray
Ahmad Al-Taee
Elizabeth Marsicano

Systemic Sclerosis Sine Scleroderma, Chronic intestinal pseudo-obstruction, Raynaud’s phenomenon


Chronic intestinal pseudo-obstruction (CIPO) is a disruption of the enteric nervous system characterized by chronic intestinal dysmotility and dilation. It has many underlying causes. We present a 52-year-old woman with 53 kg unintentional weight loss, abdominal pain, and vomiting. She had dilated small bowel loops with air fluid levels and no transition point on CT. Esophagogastroduodenoscopy (EGD) revealed aperistalsis and undigested duodenal food. The secondary cause was found to be Undifferentiated Connective Tissue Disorder (UCTD), a rheumatologic disorder that does not meet criteria for any single disease. This is the first reported case of UCTD being presented by CIPO.

Abstract 1829 | pdf Downloads 60 html Downloads 22


1. Antonucci A, Fronzoni L, Cogliandro L, et al. Chronic intestinal pseudo-
obstruction. World J Gastroenterol. 2008;14(19):2953–61.
2. Iida H, Ohkubo H, Inamori M, et al. Epidemiology and clinical experience of
chronic intestinal pseudo-obstruction in Japan: A nationwide epidemiologic survey. J Epidemiol. 2013;23(4):288–94.
3. Downes TJ, Cheruvu MS, Karunaratne TB, et al. Pathophysiology,
diagnosis, and management of chronic intestinal pseudo-obstruction.
J Clin Gastroenterol. 2018;52(6):477–89. MCG.0000000000001047
4. Wang R, Zheng B, Wang B, et al. A report of chronic intestinal pseudo-obstruction related to systemic lupus erythematosus. Open Med (Wars).
5. Zhang L, Xu D, Tian X, et al. Clinical features, morbidity, and risk factors
of intestinal pseudo-obstruction in systemic lupus erythematosus: A retrospective case-control study. J Rheumatol. 2016;43(3):559–64.
6. Zenzeri L, Tambucci R, Quitadamo P, et al. Update on chronic intestinal pseudo-obstruction. Curr Opin Gastroenterol. 2020;36(3):230–7.
7. Walcka I. Systemic sclerosis and the gastrointestinal tract. Prz Gastroenterol.
8. Calderon LM, Pope JE. Scleroderma epidemiology update. Curr
Opin Rheumatol. 2021;33(2):122–7. BOR.0000000000000785.
9. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma. Arthritis Rheum. 2000;43(2):444–51.<444::AID-ANR27>3.0.CO;2-G.
10. McFarlane, IM, Bhamra MS, Kreps A, et al. Gastrointestinal manifestations
of systemic sclerosis. Rheumatology. 2018;8(1):235.
11. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.
12. Kahn MF, Appelboom T. Syndrome de Sharp. Les maladies systemiques. 3rd
ed. 1991: 545 p.
13. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against
Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2019;71(9):1400–12. http://